1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BioInvent International AB (publ)

BioInvent International AB (publ)

BINV.ST
BioInvent International AB (publ)SE flagStockholm Stock Exchange
24.80
SEK
-0.75
- -
1.63BMarket Cap
BioInvent International AB (publ)
BINV.ST
(Stockholm Stock Exchange)

Recent

price

24.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
26.21
37.19
11.5
21.44
10.44
2.74
7.04
3.62
2.79
5.08
5.13
0.36
5.3
1.09
0.68
3.44
3.87
Revenue per Share
-40.61
-20
-50.31
-4.73
-12.01
-15.59
-6.18
-8.08
-8.91
-7.51
-2.66
-5.14
-0.69
-5.02
-6.53
-5.06
-4.44
Basic EPS, GAAP
-38.69
-18.01
-45.65
-14.35
-17
-12.59
-7.64
-7.42
-10.51
-7
-2.41
-4.78
-0.87
-5.52
-5.93
-3.88
-3.89
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-276
-278.68
-299.34
-305.88
-270.73
-224.23
-133.87
-117
-113.93
-92.11
-60.54
-38.46
-34.5
-37.25
-43.67
-48.65
- -
Book Value per Share
22.5
40.6
12.76
12.86
11.66
5.06
22.76
10.47
6.34
9.18
25.89
25.24
26.11
19.91
13.46
8.47
12.33
Tangible Book Value per Share
3
3
4
4
4
6
10
12
14
18
29
54
62
66
66
66
66
Basic Weighted Avg Shares
83
125
43
82
47
16
71
45
39
94
147
19
326
71
45
226
254
Sales/Revenue/Turnover
-154.27
-57.61
-445.62
-23
-117.02
-600.39
-88.71
-227.38
-319.3
-146.15
-50.86
-1,435.02
-15.48
-518.54
-1,054.58
-155.09
-126.58
Operating Margin (%)
9
6
6
3
2
2
1
3
5
12
12
15
15
9
19
20
20
Depreciation Expense
-128
-67
-188
-18
-54
-91
-63
-101
-123
-139
-76
-278
-43
-330
-429
-333
-292
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.26
Effective Tax Rate (%)
-154.95
-53.79
-437.4
-22.08
-115.03
-569.43
-87.8
-223.33
-319.51
-147.89
-51.8
-1,436.46
-13.03
-462.22
-960.87
-146.96
-114.84
Profit Margin (%)
60
125
41
45
46
28
225
111
70
146
720
1,057
997
1,057
848
525
775
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
9
6
22
19
15
8
1
4
LT Debt
74
138
48
49
52
29
230
130
88
169
743
1,367
1,606
1,310
886
558
811
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1,822.04
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
9
9
9
LT Borrowings
- -
- -
- -
LT Finance Leases
8
6
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
66
Market Capitalization
2,533
2,025
2,266

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
943
819
877
Cash, Cash Equivalents & STI
867
742
798
Accounts Receivable, Net
8
69
69
Inventories
11
8
10
Total Current Liabilities
95
87
102
Payables & Accruals
- -
- -
- -
ST Debt
9
9
9
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
105.18%
2.7%
-37.05%
Free Cash Flow
76.91%
148.85%
-34.7%
Net Income, GAAP
88.45%
172.94%
-22.48%
Sales/Revenue/Turnover
228.37%
357.38%
406.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6
5
13
21
45
2025
22
198
3
- -
226
2026
13
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.18
-2.09
-1.48
-1.78
-6.53
2025
-1.77
0.59
-1.91
- -
-5.06
2026
-1.81
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Karuna Therapeutics, Inc. (KRTX)
BrightPath Biotherapeutics Co., Ltd. (4594.T)
Curative Biotechnology, Inc. (CUBT)
Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
Nxera Pharma Co., Ltd. (SOLTF)
ObsEva S.A. (OBSN.SW)
Business
BioInvent International AB (publ) (Nasdaq Stockholm: BINV) is a clinical-stage biopharmaceutical company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer immunotherapy, targeting hematological cancers and solid tumors through its proprietary F.I.R.S.T™ and n-CoDeR® technology platforms. The company's lead pipeline candidates include BI-1206, an antagonistic FcγRIIB-blocking antibody in Phase 2a trials for non-Hodgkin lymphoma (NHL) and planned for first-line non-small cell lung cancer (NSCLC) in combination with pembrolizumab; BI-1808, a first-in-class anti-TNFR2 agonist antibody in Phase 2a for solid tumors and cutaneous T-cell lymphoma; BI-1910, an anti-TNFR2 antibody in Phase 1 for advanced solid tumors; BI-1607, an FcγRIIB-blocking antibody in Phase 1/2a for HER2-positive solid tumors in combination with trastuzumab; and BT-001, an oncolytic virus in Phase 1 investigator-led trials. It generates revenues from research collaborations and license agreements with partners including MSD, AstraZeneca, Transgene, and CASI Pharmaceuticals; antibody manufacturing for third parties; and royalty interests, such as the May 2025 sale of mezagitamab (TAK-079) rights to XOMA Royalty Corp. for up to USD 30 million. BioInvent maintains a fully integrated manufacturing unit and operates clinical programs across North America and Europe. Founded in 1996 and headquartered in Lund, Sweden, the company paused development of BI-1910 and BI-1607 in September 2025 to focus resources on BI-1206 and BI-1808, implementing a workforce reduction of approximately 25 positions while retaining preclinical capabilities for pipeline sustainability; this strategic shift extends cash runway into Q1 2027 pending key data readouts. Recent milestones encompass FDA IND approval for BI-1607 expansion to U.S. sites, EMA orphan drug designation and Japanese composition-of-matter patent for BI-1808, positive Phase 2a efficacy data for BI-1206 triple combination in relapsed/refractory NHL, and Clinical Trial Authorization for BI-1607 in solid tumors. It wholly owns subsidiary BioInvent Finans AB for warrant administration and reported Q3 2025 net sales of SEK 3.3 million with 122 employees as of year-end 2024.

Company News

APIChatGPT

  • accessnewswire.com

    BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025